

Gilead Sciences launches Asia Pacific ALL4LIVER Grant 2021 with focus on hepatitis B

28 July 2021 | News

Inaugural cycle of the grant will focus on Hepatitis B awareness initiatives



American biopharma firm Gilead Sciences, Inc. has announced the launch of the 2021 Gilead Asia Pacific ALL4LIVER Grant, a new grant program to support local communities in strengthening liver disease education efforts across Asia Pacific.

This biennial grant will support community-led projects that can help improve liver health for people living in the region. The focus of 2021's grant program is on chronic hepatitis B under the theme, "Empowerment Through Education".

The ALL4LIVER Grant, which will run every two years, aims to empower organizations that can help bring liver health, in particular viral hepatitis, to the forefront of public health initiatives and address the unmet needs in the region.

The program was inspired by a regional study, conducted by Gilead, which found critical gaps in the public awareness and attitudes towards viral hepatitis.

The 2021 ALL4LIVER Grant cycle is open to community groups in 11 countries/territories in Asia Pacific: Singapore, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, South Korea, Taiwan, Thailand, and Vietnam.

This year's version of the grant seeks to support projects in hepatitis B with a focus on strengthening peer support, improving awareness and health literacy, and the development of digital platforms or innovative tools for education